Abstract
Human papillomavirus (HPV) causes cervical cancer, which is the fourth most common cancer in women. Most of the cervical cancers are linked to genital infection with HPV and it is the most common viral infection of the reproductive tract. At present, there are three types of HPV vaccines available. Even though HPV vaccination is a primary prevention tool, that does not eliminate the need for routine cervical screening, since the vaccines do not protect against all high-risk HPV types. Ninety percent of HPV infections have no clinical consequences at all whether they are high-risk or low-risk subtypes of HPV. All three types of HPV vaccines have very high vaccine efficacy for prevention of HPV infection among females aged 14 to 26 years. Proper assessment of the safety of HPV vaccine is a problem even after proper systematic review since the most of the clinical trials on the safety of the vaccines were used Hepatitis A vaccine or high immunogenicity enhancing aluminium adjuvant as their placebo. HPV vaccination would be very cost effective for the countries when there is no cervical screening program or if the programme coverage is very poor.Bangladesh Journal of Medical Science Vol.17(3) 2018 p.329-336
Highlights
Cervical cancer is the fourth most common cancer in women
Around 85% of the global burden cervical cancer occurs in the less developed regions, where it accounts for almost 12% of all female cancers.Human papillomavirus (HPV) infections are transmitted through sexual contacts[1]
Even though HPV vaccination is a primary prevention tool, that does not eliminate the need for routine cervical screening[2]
Summary
Cervical cancer is the fourth most common cancer in women. ‘Human Papilloma Virus’ (HPV) is the most common cause behind cervical cancer. Around 85% of the global burden cervical cancer occurs in the less developed regions, where it accounts for almost 12% of all female cancers.HPV infections are transmitted through sexual contacts[1]. Well organised screening programmes have been responsible for reducing the cervical cancer burden in the developed countries during last few decades. Even though HPV vaccination is a primary prevention tool, that does not eliminate the need for routine cervical screening[2]. This review provides an overview of key information, on the use of HPV vaccination as a preventive strategy of cervical cancers, for policy makers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
